Herein, in this opinion, we discuss how phosphoproteomics-guided analysis of tau phosphorylation is redefining biomarker strategies in both AD and ALS, bridging two diseases once considered molecularly distinct. The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.